Dermal Mycosis Market Research Report 2025-2026 & 2035, Competitive Analysis of Bayer, Kenvue, Karo Healthcare, Novartis, Glenmark Pharmaceuticals, Sun Pharma, Teva, and Sandoz [Yahoo! Fin...
Kenvue Inc. (KVUE)
Company Research
Source: Yahoo! Finance
in antifungal therapies, and rising tropical populations. Common fungal pathogens include Trichophyton, Epidermophyton, and Candida, with rising demand for effective topical and systemic treatments. Innovations in antifungal formulations and diagnostics, including nanopharmaceuticals and molecular assays, enhance drug efficacy and early detection. Despite challenges like antifungal resistance, the market is buoyed by consumer awareness, OTC product uptake, and emerging market growth. Companies like Bayer, Kenvue, and Novartis are leading with strategic collaborations and R&D investments, aimed at expanding antifungal portfolios and innovations. Dublin, April 28, 2026 (GLOBE NEWSWIRE) -- The "Dermal Mycosis Market - A Global and Regional Analysis: Focus on Drug Type and Region, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The competitive landscape of the dermal mycosis market includes leading pharmaceutical companies such as Bayer AG, Kenvue Inc., Karo Hea
Show less
Read more
Impact Snapshot
Event Time:
KVUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KVUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KVUE alerts
High impacting Kenvue Inc. news events
Weekly update
A roundup of the hottest topics
KVUE
News
- Kenvue Declares Quarterly Cash DividendBusiness Wire
- Why Kenvue Inc. (KVUE) is One of the Best Cheap Stocks to Buy Under $20 [Yahoo! Finance]Yahoo! Finance
- Kenvue to Announce First Quarter 2026 Results on May 7, 2026Business Wire
- Kenvue (KVUE) had its price target lowered by Citigroup Inc. from $20.00 to $19.00. They now have a "neutral" rating on the stock.MarketBeat
- Kimberly-Clark Announces Post-Closing Organizational Structure and Identifies Key Leadership [TheStreet.com]TheStreet.com
KVUE
Earnings
- 2/17/26 - Beat
KVUE
Sec Filings
- 4/15/26 - Form 8-K
- 4/8/26 - Form ARS
- 4/8/26 - Form DEFA14A
- KVUE's page on the SEC website